Seoul, South Korea

Seoul has solidified its position as a premier global destination for biotechnology and pharmaceutical R&D, characterized by a sophisticated convergence of deep science and digital technology.

The city is world-renowned for its leadership in advanced biologics manufacturing and biosimilars, anchored by industry titans and a dense network of Contract Development and Manufacturing Organizations (CDMOs).

Beyond large-scale production, Seoul is a hotbed for healthcare innovation, particularly in AI-driven drug discovery and the development of next-generation medical devices integrated with 5G infrastructure.

The ecosystem is supported by prestigious academic research institutions and world-class clinical facilities, such as the Asan Institute for Life Sciences, which facilitate rapid translational medicine and complex clinical trials.

Startups thrive within specialized clusters like Seoul Biohub, benefiting from significant venture capital investment and the South Korean government’s commitment to "National Strategic Technologies."

Currently, the region is leading the charge in cell and gene therapies, antibody-drug conjugates (ADCs) and regenerative medicine, making it a critical partner for global out-licensing deals.

As a pioneer in digital health transformation, Seoul continues to redefine patient care through AI-powered diagnostics and decentralized clinical trial models.

This unique blend of manufacturing rigor, high-tech integration and elite research makes Seoul an indispensable pillar of the global life sciences ecosystem.